Show simple item record

dc.contributor.authorFernando, S
dc.contributor.authorConway, A
dc.contributor.authorMitchell, H
dc.contributor.authorSandri, I
dc.contributor.authorWardley, Andrew M
dc.contributor.authorOkonta, L
dc.contributor.authorMansi, J
dc.date.accessioned2017-05-19T15:12:48Z
dc.date.available2017-05-19T15:12:48Z
dc.date.issued2017-03
dc.identifier.citationA two-centre audit on changes in ejection fraction (EF) following sequential anthracycline chemotherapy and trastuzumab (T) in patients with HER2+early breast cancer (EBC). 2017, 32(Suppl 1): S128 The Breasten
dc.identifier.issn09609776
dc.identifier.doi10.1016/S0960-9776(17)30399-5
dc.identifier.urihttp://hdl.handle.net/10541/620374
dc.language.isoenen
dc.relation.urlhttp://linkinghub.elsevier.com/retrieve/pii/S0960977617303995en
dc.rightsArchived with thanks to The Breasten
dc.titleA two-centre audit on changes in ejection fraction (EF) following sequential anthracycline chemotherapy and trastuzumab (T) in patients with HER2+early breast cancer (EBC).en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentGuys and St Thomas NHS FT, Londonen
dc.identifier.journalThe Breasten


Files in this item

This item appears in the following Collection(s)

Show simple item record